<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FB3771A2-0EB5-4FC9-B103-BDBD224F1BDD"><gtr:id>FB3771A2-0EB5-4FC9-B103-BDBD224F1BDD</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Pugh</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F127"><gtr:id>71C144BB-767C-47A8-86A5-243DDD086803</gtr:id><gtr:title>Regulation of gene expression by the hypoxia-inducible factor-1 complex in mammals and caenorhabditis elegans</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/127</gtr:grantReference><gtr:abstractText>Correct supply of oxygen is essential for the normal function of cells in multicellular organisms. Errors in oxygen supply to the tissue frequently occur in diseases such as heart attack and cancer, often limiting successful treatment. A gene regulatory mechanism underlies processes balancing oxygen consumption and delivery. Central to this mechanism is a protein complex called hypoxia-inducible factor-1 (HIF) which binds to the regulatory DNA of particular genes and activities them in low oxygen conditions, resulting in increased oxygen supply to the tissues and reduced oxygen demand. The dominant mechanism regulating this protein complex is the rapid destruction of the HIF alpha component when oxygen is present. I have identified the region of the HIF alpha proteins responsible for this effect and now propose detailed analysis of how oxygen destabilises it. Intriguingly, this mechanism is evoultionary conserved in nematode worms. These worms have particular attributes which all facilitate dissection of this mechanism. Combined studies on the mammalian and worm systems should synergise, advancing our understanding substantially. Protein fragments have been identified that can up-regulate HIF activity in cells. I will define how this occurs and establish their use to modulate this system artifically for therapeutic benefit in model systems.</gtr:abstractText><gtr:technicalSummary>Errors in oxygen homeostasis contribute to the pathophysiology of many diseases. A widespread genetic mechanism of oxygen homeostasis based on hypoxia-inducible factor-1 (HIF) contributes to matching oxygen supply and demand in multicellular organisms. HIF activates transcription of specific genes in hypoxia. HIF is regulated by oxygen at a number of levels but post-translational events leading to normoxic ubiquitylation and proteasomal destruction of HIF alpha subunits exert a dominant effect.

My objectives in this fellowship are to:
1) determine oxygen-regulated mechanisms which trigger HIF alpha chain destruction and to identify more distant influences on this pathway, addressed initially by further characterising the interaction of HIF alpha chains with the von Hippel Lindau tumour suppressor protein. Biochemical investigation of modifications in these proteins retrieved from stably transfected cell lines will give a biological background to parallel studies investigating the mechanisms of degeneration of recombinant proteins in vitro
2) investigate the orthologus gene regulatory mechnanism in C. elegans and use it to illuminate studies of the mammalian system. Informative approaches include identifying mutant worms with defects in this pathway to define up-stream processes, identifying conserved residues critical for functional interactions between proteins and using gene arrays to identify downstream genes.
3) develop peptides which interfere with HIF alpha chain destruction and investigate their effects in vivo. Peptide induced HIF activation will be optimised in cell lines. Effects of optimised peptides will be examined in transgenic animals and ultimately in models of ischaemic injury, setting the scene for potential therapeutic uses in humans.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-10-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>978635</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Collaboration with Stuart Egginton</gtr:description><gtr:id>691A28C1-A3F1-43E5-BD94-C05444A698DA</gtr:id><gtr:impact>Publications pre-dating the e-val period.
On-going collaborative work - not yet reached publication.</gtr:impact><gtr:outcomeId>95BCF6C4354-1</gtr:outcomeId><gtr:partnerContribution>Exchange of methods and technical know-how.</gtr:partnerContribution><gtr:piContribution>Application of hypoxia signalling pathway knowledge to studies on angiogenesis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Collaboration with Keith Buckler</gtr:description><gtr:id>D2CBF32E-B88E-4CCE-9F74-4E638E3723D2</gtr:id><gtr:impact>Grant application currently under review with MRC</gtr:impact><gtr:outcomeId>qXF6ZsG3LhR-1</gtr:outcomeId><gtr:partnerContribution>Knowledge of carotid body physiology</gtr:partnerContribution><gtr:piContribution>Provision of gentically manipulated mice and analysis of their carotid body morphology and ventilatory phenotype.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Longstanding collaboration with Chris Schofield</gtr:description><gtr:id>1A2D2A78-9C3E-485A-A11E-F4164D18DA7E</gtr:id><gtr:impact>A variety of publications documented in e-val.</gtr:impact><gtr:outcomeId>0A550D4DA6F-1</gtr:outcomeId><gtr:partnerContribution>Facilities and environment</gtr:partnerContribution><gtr:piContribution>Collaborative studies on 2-oxoglutarate dependent dioxygenases</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU COST action</gtr:description><gtr:id>CD95AEE4-0C97-47EB-A00C-C936C40611E0</gtr:id><gtr:impact>Hypoxianet meeting in Dublin - multidisciplinary with Chemistry and Pharmaceutical Industry.</gtr:impact><gtr:outcomeId>H5yT7mcraf3-1</gtr:outcomeId><gtr:partnerContribution>Intellectual exchange / training</gtr:partnerContribution><gtr:piContribution>Intellectual exchange. 
Management committee membership</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Structural Biology</gtr:department><gtr:description>Collaborations in structural biology with Yvonne Jones and Dave Stuart</gtr:description><gtr:id>89112189-961A-4FBD-A4E6-BE0B25040794</gtr:id><gtr:impact>Publications pre-dating e-val.</gtr:impact><gtr:outcomeId>FED2EC150E3-1</gtr:outcomeId><gtr:partnerContribution>Collaborative solution of structural problems and generation of recombinant proteins.</gtr:partnerContribution><gtr:piContribution>Collaborative solution of structural problems and generation of relevant recombinant proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Collaborations with Peter Robbins</gtr:description><gtr:id>6B1BFB44-9DE9-45FC-84B4-5D762A8C2DAF</gtr:id><gtr:impact>Publications documented in e-val and those pre-dating this period.
New grant application.</gtr:impact><gtr:outcomeId>9C5921FAFB4-1</gtr:outcomeId><gtr:partnerContribution>Studies on human subjects</gtr:partnerContribution><gtr:piContribution>Collaborations studying effects of hypoxia and genetic mutations in the hIF pathway in human subjects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Longstanding collaboration with Peter Ratcliffe</gtr:description><gtr:id>1C84A614-15DE-4686-8CAF-888732A10570</gtr:id><gtr:impact>Publications and patents as documented elsewhere in e-val</gtr:impact><gtr:outcomeId>21B540BBC49-1</gtr:outcomeId><gtr:partnerContribution>Facilities and environment</gtr:partnerContribution><gtr:piContribution>A synergistic collaboration on hypoxia biology since 1990</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Local radio interview</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>28A49009-D223-48FB-8551-9C6F45F7A8C8</gtr:id><gtr:impact>Local radio interview

No subsequent impact</gtr:impact><gtr:outcomeId>8823D40202A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>24751353-FFE8-473F-A3AC-F441B3686B49</gtr:id><gtr:impact>30 pupils attended aninteractive seminar.


One pupil has subsequently asked to come and gain some work experience with me.</gtr:impact><gtr:outcomeId>Zjx77SWeQL8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Six counties kidney patients association</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>ABCCEC63-9C66-456E-A9AC-C940E971127C</gtr:id><gtr:impact>Provision of a research update at their Annual General meeting

Greater patient awareness of what I and my team do.</gtr:impact><gtr:outcomeId>4C682BE5AB1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>FP7 consortium</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>093B9350-03AA-449D-9B17-11039A12D8B9</gtr:id><gtr:outcomeId>4853F1DE2DA0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Charitable Trust</gtr:description><gtr:end>2006-10-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>41D6098A-799E-40DD-800B-A6ED45CC1EC5</gtr:id><gtr:outcomeId>8AF1A92BA010</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Centre of Research Excellence</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>5BD8F9FD-1D93-45BD-B731-4E0BF553047E</gtr:id><gtr:outcomeId>80FF3FF02CA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>911B120F-9E19-4718-A3E9-42940B6FF52E</gtr:id><gtr:outcomeId>C933202F0A70</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>3D3D9152-8F57-4184-8A81-CCC99A2A35B7</gtr:id><gtr:outcomeId>88442ACC1DC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEFCE Tenured Post</gtr:description><gtr:end>2022-04-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>4AE325C2-356F-4486-A7D2-B1FA9A64044C</gtr:id><gtr:outcomeId>14A77FC89840</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>UK patent 0118952 Compounds, methods and means for the modulation of prolyl hydroxylases that act on HIF alpha chains.</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>34E52D50-A136-4F0F-B82E-0B1B550524F3</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>4D365749C7B</gtr:outcomeId><gtr:patentId>EP1379630</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Hydroxyproline inhibitors</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>UK patent 0030504 Methods for identifying genes whose expression is regulated by von Hippel Lindau tumour supproessor factor.</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>AAD0FC05-5297-4A56-9EE0-A7975815D87A</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>3CF55FB5CB2</gtr:outcomeId><gtr:patentId>JP2009022287?</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>von Hippel Lindau tumour suppressor</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Compounds which modulate 2-oxoglutaray=te dependent oxygenases.</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>A433A9CD-77AE-4174-B0BC-C3B1ECF467CF</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>491037DFFC9</gtr:outcomeId><gtr:patentId>AU2009202216</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Further HIF inhibitors</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>UK patent number 9911047 - assays based on the interaction between HIF and VHL proteins</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>EF6687C5-DB12-4CD1-87D6-E0A6A328F9B8</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>E53D25E60F1</gtr:outcomeId><gtr:patentId>US6787326</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Ischaemia therapeutics</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>UK patent 0211920 The modulation of hydroxylases which are involved in activation of HIF related activity.</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>949123D3-909D-4126-9D39-BA66B62CB7F1</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>1F64E820CD2</gtr:outcomeId><gtr:patentId>EP1506409</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>HIF asparaginyl hydroxylase</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>UK patent 0030502 Constructs comprising hypoxia response elements and their use in targetting of therapeutic genes to cells such as tumour celss which are under conditions of hypoxia.</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>85BA0DE6-7A7B-43DA-A5A1-17CB40C2C1C5</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>4DA235C5D4D</gtr:outcomeId><gtr:patentId>JP2009050260</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>HRE technology</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>UK patent 0107123 Means to modulate the effects of the HIF alpha chains in cells.</gtr:description><gtr:grantRef>G116/127</gtr:grantRef><gtr:id>9BCE4A13-66F5-4BFB-9A55-38A190664B31</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>81AC9F02996</gtr:outcomeId><gtr:patentId>EP1379630</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Hydroxyproline</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>RCC4 renal carcinoma cell line stably complemented with wild type VHL expression plasmid or the empty expression plasmid</gtr:description><gtr:id>76504645-0313-42C9-9E76-C036E42D7EFA</gtr:id><gtr:impact>These lines have been used in the elucidation of the HIF pathway. They have been deposited at ECACC for wider use by the scientific community.</gtr:impact><gtr:outcomeId>BC68D96DC63</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RCC4+wtVHL; RCC4 empty vector</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>https://www.phe-culturecollections.org.uk/products/celllines/generalcell/search.jsp?searchtext=RCC4&amp;dosearch=true</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>THis is an HT1080 cell line stably transfected to express a HIF responsive luciferase construct as a reporter line for assays of the HIF pathway</gtr:description><gtr:id>DFF57DF8-C52A-4B64-9B36-D722541130D7</gtr:id><gtr:impact>This cell line has been used for drug screening in the academic and commercial sectors.</gtr:impact><gtr:outcomeId>2EA889D1060</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HT1080-P8</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>ReOx Ltd.</gtr:companyName><gtr:description>ReOx is a drug discovery company that aims to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).</gtr:description><gtr:id>499EFD67-E637-407D-A40A-FFD18E476099</gtr:id><gtr:impact>ReOx reached a licensing agreement with a US pharmaceutical company.</gtr:impact><gtr:outcomeId>F6B2B38B657</gtr:outcomeId><gtr:url>http://www.isis-innovation.com/news/news/reox-aug03.html</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>DE335663-01AB-47E8-87BB-E288474C8A0F</gtr:id><gtr:title>Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f9efcf7d9dd79b733acabce34dfa52"><gtr:id>e0f9efcf7d9dd79b733acabce34dfa52</gtr:id><gtr:otherNames>Smith TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>B2A5042E1D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52AB40A6-438C-4696-B9BA-296C191479B8</gtr:id><gtr:title>HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fdac9032ead5d30fb254632f9607944"><gtr:id>4fdac9032ead5d30fb254632f9607944</gtr:id><gtr:otherNames>Willam C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn><gtr:outcomeId>D2A19E40455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>280DAD9D-7C22-4067-A6CE-8629BCDD21BC</gtr:id><gtr:title>Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH).</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e242697e08b3595bb58b220c4e43f7b"><gtr:id>4e242697e08b3595bb58b220c4e43f7b</gtr:id><gtr:otherNames>Cockman ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>04729125A5A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B19C1D2-32C2-467C-ADCA-DD29F03D7AEE</gtr:id><gtr:title>Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9465733566f92ed7f0e4a4c2f9d1e16f"><gtr:id>9465733566f92ed7f0e4a4c2f9d1e16f</gtr:id><gtr:otherNames>Grosfeld A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>81734E90485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DED21F76-D5BF-4AF3-B3D8-B4E9061C11DF</gtr:id><gtr:title>Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be2abbb74b87af17964ff09dad0f5fd1"><gtr:id>be2abbb74b87af17964ff09dad0f5fd1</gtr:id><gtr:otherNames>Lau KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>4BEA3CFCA3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B40D41-AA83-466E-8F49-22CEB144B182</gtr:id><gtr:title>Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edeb76ec9584c9365930d349525b1cca"><gtr:id>edeb76ec9584c9365930d349525b1cca</gtr:id><gtr:otherNames>Jones DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>2A1B3F6C07C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/127</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>